



COVID-19 Antigen Rapid Test with AnteoBind™

AnteoTech is developing a high sensitivity, low cost rapid test for the detection of SARS-CoV-2 antigen

AnteoTech is seeking partnerships to trial our COVID-19 Antigen Test

We are offering the opportunity to try our test in your laboratory and distribution setting. If you would like to participate in either or both, please let us know:

- + **estimated volume of tests that you would like to try**
- + **geographies into which you would like to distribute**

Contact us at sales@anteotech.com and we will provide you with the next steps.

About Our Development

- + Low-cost, easy-to-use rapid diagnostic antigen test for the detection of SARS-CoV-2 antigen
- + Reader-based fluorescent particle detection method for high sensitivity
- + Expected launch to market in Q1 2021
- + Uses nasal swab specimens and currently developing a saliva format test expected to be launched in 2021

Key Attributes


- + Delivery of test result within 15 minutes
- + Highly sensitive test that detects SARS-CoV-2 antigen **early in the infection cycle allowing faster clinical intervention if needed**
- + Uses AnteoBind technology for improved test accuracy

anteotech.com


Product Development

From our testing so far, the AnteoTech COVID-19 Antigen Rapid Test can detect confirmed positive and negative samples. As shown below, the data demonstrates a strong positive viral signal from 10 of the samples and a very low signal from 5 of the samples with estimated positive/negative cut-off value at 230 RFU.

Sample #	Reading Test line Signal (RFU)	RT-PCR Confirmed
1	580	Positive
2	12960	Positive
3	1230	Positive
4	5740	Positive
5	680	Positive
6	290	Positive
7	9560	Positive
8	450	Positive
9	5240	Positive
10	13800	Positive
11	110	Negative
12	110	Negative
13	110	Negative
14	210	Negative
15	130	Negative



How will the AnteoTech COVID-19 Antigen Rapid Test work?



Market Information

- + Final pricing to be announced Q1 2021
- + Distributor pricing will be competitive with reader-based COVID-19 antigen tests currently in the market
- + Future releases will include COVID-19 antigen and Flu A/Flu B multiplex on a single test
- + Available in COVID-19 stand-alone format in Q1 2021 with TGA, FDA (EUA) and CE approval
- + AnteoTech expect final manufacturing costs to be the same as similar types of lateral flow tests
- + Approvals for market access will be procured upon partnership with distributors

What should the AnteoTech COVID-19 Antigen Rapid Test be used for?

- + To be used by trained clinicians in the clinical or point-of-care setting
- + For population screening for travel, events and densely populated areas
- + For businesses such as mine sites, office and remote operations

Contact AnteoTech Sales

T + 61 7 3219 0085 (AUS)
E sales@anteotech.com



FS709936

MD723665

